Рецепт. 2019; 22: 900-912
Основные принципы лечения остеопороза
Аннотация
Остеопороз (ОП) – хроническое системное заболевание скелета, которое характеризуется уменьшением костной массы и развитием нарушений микроархитектуры костной ткани, что приводит к снижению прочности кости и предрасположенности к патологическим переломам. Высокие социальные и личные затраты пациентов на лечение ОП создают проблемы для здоровья населения и системы здравоохранения в целом, потому что большинство пациентов с остеопорозом остаются без медикаментозной терапии. В статье освещены вопросы медикаментозной терапии, направленной на улучшение качества костной ткани с целью снижения риска остеопоротических переломов.
Список литературы
1. Kanis J.A., Cooper C., Rizzoli, Reginster J.-Y. (2018) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International, vol. 12, September. Available at: https://doi.org/10.1007/s00198-018-4704-5
2. Ramanau H., Chernyanin I., Rudenka E. (2018) Epidemiology of hip fracture in Belarus: development of a country-specific FRAX model and its comparison to neighboring country models. Archives of Osteoporosis, vol. 13, pp. 42.
3. International Osteoporosis Foundation (2019) Facts and statistics about osteoporosis and its implications. Available at: www.iofbonehealth.org/facts-and-statistics.html
4. Harvey N.C., Biver E., Kaufman J.M. (2017) The role of calcium supplementation in healthy musculoskeletal ageing: An expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF). Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol. 28, pp. 447–462.
5. Hiligsmann M., Ben Sedrine W., Bruyere O. (2015) Cost-effectiveness of vitamin D and calcium supplementation in the treatment of elderly women and men with osteoporosis. European journal of public health, vol. 25, pp. 20–25.
6. Bischoff-Ferrari H.A., Dawson-Hughes B., Staehelin H.B. (2009) Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ (Clinical research ed), vol. 33, pp. 3692.
7. Bischoff-Ferrari H.A., Willett W.C., Orav E.J. (2012) A pooled analysis of vitamin D dose requirements for fracture prevention. The New England journal of medicine, vol. 367, pp. 40–49.
8. Smith H., Anderson F., Raphael H. (2007) Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford, England), vol. 46, pp. 1852–1857.
9. Sanders K.M., Stuart A.L., Williamson E.J. (2010) Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. Jama, vol. 303 pp. 1815–1822.
10. Kanis J.A., McCloskey E.V., Johansson H. (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int., vol. 24, no 1, pp. 23–57.
11. Wong R.M.Y., Law S.W., Lee K.B. (2019) Secondary prevention of fragility fractures: instrumental role of a fracture liaison service to tackle the risk of imminent fracture. Hong Kong Med. J., vol. 25, pp. 235–42.
12. Adler R.A., El-Hajj Fuleihan G., Bauer D.C. (2016) Managing Osteoporosis Patients after Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. Bone Miner. Res., vol. 31(1), pp. 16–35.
13. Kanis J.A., Burlet N., Cooper C. (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int., vol. 19, pp. 399–428.
14. Schnitzer T. Bone H.G., Crepaldi G. (2000) Тherapeutic equivalence of alendronate 70 mg once weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano), vol. 12, pp. 1–12.
15. McClung M., Harris S.T., Miller P.D. (2013) Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am. J. Med., vol. 126, pp. 13–20.
16. Rogers M.J., Crockett J.C., Coxon F.P. (2011) Biochemical and molecular mechanisms of action of bisphosphonates. Bone, vol. 49, pp. 34–41.
17. Pols H.A., Felsenberg D., Hanley D.A. (2011) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int., vol. 9, no 5, pp. 461–8.
18. Black D.M., Thompson D.E., Bauer D.C. (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J. Clin Endocrinol Metab., vol. 85, no 11, pp. 4118–24.
19. Black D.M., Schwartz A.V., Ensrud K.E. (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA, vol. 296, no 24, pp. 2927–2938.
20. Black D.M., Delmas P.D., Eastell R. (2007) HORIZON Pivotal Fracture Trial Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med., vol. 18, no 356, pp. 1809–1822.
21. Lyles K.W., Colón-Emeric C.S., Magaziner J.S. (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N. Engl. J. Med., vol. 357(18), pp. 1799–809. doi: 10.1056/NEJMoa074941. Epub 2007 Sep 17.
22. Black D.M., Reid I.R., Boonen S. (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J. Bone Miner Res., vol. 27, no 2, pp. 243–54. doi: 10.1002/jbmr.1494.
23. McClung M., Harris S.T., Miller P.D. (2013) Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am. J. Med., vol. 126, pp. 13–20.
24. Marozik P., Alekna V., Rudenko E., Tamulaitiene M., Rudenka A., Mastaviciute A., Samokhovec V., Cernovas A., Kobets K., Mosse I. (2019) Bone metabolism genes variation and response to bisphosphonate treatment in women with postmenopausal osteoporosis. PLoS ONE, vol. 14, no 8: e0221511, pp. 1–14. Available at: https://doi.org/10.1371/journal.pone.0221511IF2.776
25. Hadji P., Gamerdinger D., Spieler W. (2012) Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass. Osteoporos. Int., vol. 23, pp. 625–633.
26. Chiha M. (2013) Long-term follow-up of patients on drug holiday from bisphosphonates: real-world setting. Endocr. Pract., vol. 19, no 6, pp. 989–994.
27. Lecart M.P., Reginster J.Y. (2011) Current options for the management of postmenopausal osteoporosis. Expert opinion on pharmacotherapy, vol. 12, pp. 2533–2552.
28. Cummings S.R., San Martin J., McClung M.R. (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. The New England journal of medicine, vol. 361, pp. 756–765.
29. Bone H.G., Wagman R.B., Brandi M.L. (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. The lancet Diabetes & endocrinology, vol. 5, pp. 513–523.
30. Rudenko E.V., Alekna V., Tamulyajtiene M., Rudenko E.V., Samohovec O.YU., Adamenko A.V. (2019) Opyt primeneniya denosumaba dlya lecheniya postmenopauzal’nogo osteoporoza. Medicinskie novosti, no 10, pp. 22.
31. Diez Perez A., Adachi J.D., Agnusdei D. (2012) Treatment failure in jsteoporosis. Ostoporosis Int., vol. 23, pp. 2769–2774.
Recipe. 2019; 22: 900-912
Basic Principles of Osteoporosis Treatment
Abstract
Osteoporosis (OP) is a chronic systemic disease of the skeleton, which is characterized by a decrease in bone mass and the development of violations of the bone microarchitecture, which leads to a decrease in bone strength and a predisposition to pathological fractures. The high social and personal expenses of patients for the treatment of osteoporosis (OP) create problems for the health of the population and the health system as a whole because most patients with osteoporosis remain without drug therapy. The article highlights the issues of drug therapy for the purposes of improving the quality of bone tissue in order to reduce the risk of osteoporotic fractures.
References
1. Kanis J.A., Cooper C., Rizzoli, Reginster J.-Y. (2018) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International, vol. 12, September. Available at: https://doi.org/10.1007/s00198-018-4704-5
2. Ramanau H., Chernyanin I., Rudenka E. (2018) Epidemiology of hip fracture in Belarus: development of a country-specific FRAX model and its comparison to neighboring country models. Archives of Osteoporosis, vol. 13, pp. 42.
3. International Osteoporosis Foundation (2019) Facts and statistics about osteoporosis and its implications. Available at: www.iofbonehealth.org/facts-and-statistics.html
4. Harvey N.C., Biver E., Kaufman J.M. (2017) The role of calcium supplementation in healthy musculoskeletal ageing: An expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF). Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol. 28, pp. 447–462.
5. Hiligsmann M., Ben Sedrine W., Bruyere O. (2015) Cost-effectiveness of vitamin D and calcium supplementation in the treatment of elderly women and men with osteoporosis. European journal of public health, vol. 25, pp. 20–25.
6. Bischoff-Ferrari H.A., Dawson-Hughes B., Staehelin H.B. (2009) Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ (Clinical research ed), vol. 33, pp. 3692.
7. Bischoff-Ferrari H.A., Willett W.C., Orav E.J. (2012) A pooled analysis of vitamin D dose requirements for fracture prevention. The New England journal of medicine, vol. 367, pp. 40–49.
8. Smith H., Anderson F., Raphael H. (2007) Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford, England), vol. 46, pp. 1852–1857.
9. Sanders K.M., Stuart A.L., Williamson E.J. (2010) Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. Jama, vol. 303 pp. 1815–1822.
10. Kanis J.A., McCloskey E.V., Johansson H. (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int., vol. 24, no 1, pp. 23–57.
11. Wong R.M.Y., Law S.W., Lee K.B. (2019) Secondary prevention of fragility fractures: instrumental role of a fracture liaison service to tackle the risk of imminent fracture. Hong Kong Med. J., vol. 25, pp. 235–42.
12. Adler R.A., El-Hajj Fuleihan G., Bauer D.C. (2016) Managing Osteoporosis Patients after Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. Bone Miner. Res., vol. 31(1), pp. 16–35.
13. Kanis J.A., Burlet N., Cooper C. (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int., vol. 19, pp. 399–428.
14. Schnitzer T. Bone H.G., Crepaldi G. (2000) Therapeutic equivalence of alendronate 70 mg once weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano), vol. 12, pp. 1–12.
15. McClung M., Harris S.T., Miller P.D. (2013) Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am. J. Med., vol. 126, pp. 13–20.
16. Rogers M.J., Crockett J.C., Coxon F.P. (2011) Biochemical and molecular mechanisms of action of bisphosphonates. Bone, vol. 49, pp. 34–41.
17. Pols H.A., Felsenberg D., Hanley D.A. (2011) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int., vol. 9, no 5, pp. 461–8.
18. Black D.M., Thompson D.E., Bauer D.C. (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J. Clin Endocrinol Metab., vol. 85, no 11, pp. 4118–24.
19. Black D.M., Schwartz A.V., Ensrud K.E. (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA, vol. 296, no 24, pp. 2927–2938.
20. Black D.M., Delmas P.D., Eastell R. (2007) HORIZON Pivotal Fracture Trial Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med., vol. 18, no 356, pp. 1809–1822.
21. Lyles K.W., Colón-Emeric C.S., Magaziner J.S. (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N. Engl. J. Med., vol. 357(18), pp. 1799–809. doi: 10.1056/NEJMoa074941. Epub 2007 Sep 17.
22. Black D.M., Reid I.R., Boonen S. (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J. Bone Miner Res., vol. 27, no 2, pp. 243–54. doi: 10.1002/jbmr.1494.
23. McClung M., Harris S.T., Miller P.D. (2013) Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am. J. Med., vol. 126, pp. 13–20.
24. Marozik P., Alekna V., Rudenko E., Tamulaitiene M., Rudenka A., Mastaviciute A., Samokhovec V., Cernovas A., Kobets K., Mosse I. (2019) Bone metabolism genes variation and response to bisphosphonate treatment in women with postmenopausal osteoporosis. PLoS ONE, vol. 14, no 8: e0221511, pp. 1–14. Available at: https://doi.org/10.1371/journal.pone.0221511IF2.776
25. Hadji P., Gamerdinger D., Spieler W. (2012) Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass. Osteoporos. Int., vol. 23, pp. 625–633.
26. Chiha M. (2013) Long-term follow-up of patients on drug holiday from bisphosphonates: real-world setting. Endocr. Pract., vol. 19, no 6, pp. 989–994.
27. Lecart M.P., Reginster J.Y. (2011) Current options for the management of postmenopausal osteoporosis. Expert opinion on pharmacotherapy, vol. 12, pp. 2533–2552.
28. Cummings S.R., San Martin J., McClung M.R. (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. The New England journal of medicine, vol. 361, pp. 756–765.
29. Bone H.G., Wagman R.B., Brandi M.L. (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. The lancet Diabetes & endocrinology, vol. 5, pp. 513–523.
30. Rudenko E.V., Alekna V., Tamulyajtiene M., Rudenko E.V., Samohovec O.YU., Adamenko A.V. (2019) Opyt primeneniya denosumaba dlya lecheniya postmenopauzal’nogo osteoporoza. Medicinskie novosti, no 10, pp. 22.
31. Diez Perez A., Adachi J.D., Agnusdei D. (2012) Treatment failure in jsteoporosis. Ostoporosis Int., vol. 23, pp. 2769–2774.
